F10 and cancer: It was shown that treating patients who have an active cancer diagnosis with apixaban, a Factor Xa inhibitor, is associated with a reduced risk of recurrent VTE without increasing bleeding risk, compared to other DOACs such as edoxaban and rivaroxaban [117].